Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $186.68M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.23M
Average 0.26M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Intrinsic Alpha fair value
Locked
Current Price
$6.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -70.7% | +142.5% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -70.7% over three years. Forward estimates point to Revenue at +142.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc. NASDAQ:EPRX | $548.02M | $8.15 | Not rated | -8.5 | +3.92% |
Avalo Therapeutics, Inc. NASDAQ:AVTX | $448.71M | $7.76 | Not rated | -3.6 | -60.39% |
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | $435.76M | $7.25 | Not rated | -2.8 | +64.78% |
Fennec Pharmaceuticals Inc. NASDAQ:FENC | $407.48M | $11.62 | Not rated | -36.3 | +55.20% |
Nautilus Biotechnology, Inc. NASDAQ:NAUT | $295.50M | $2.32 | Not rated | -4.9 | +6.79% |
Inventiva S.A. NASDAQ:IVA | $191.29M | $3.68 | Not rated | -5.5 | -22.97% |
MediWound Ltd. NASDAQ:MDWD | $166.54M | $12.90 | Not rated | -7.0 | -25.16% |
Neonc Technologies Holdings, Inc. NASDAQ:NTHI | $141.66M | $4.91 | Not rated | -3.0 | -38.67% |
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD | $29.11M | $1.33 | Not rated | -1.2 | -59.86% |
Continue the stock analysis
Jump to another research area for this company.